Bausch Health Companies Inc. cash flow to debt ratio of 6.60% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bausch Health Companies Inc.'s free cash flow has decreased 20.40% from $1.26B last year to $1.00B, signaling decreasing performance

Bausch Health Companies Inc.'s debt to equity ratio is -11.73, signaling that the company spent its equity and risk bankruptcy.

Bausch Health Companies Inc.'s debt has increased relative to shareholder equity from -17.06 last year to -11.73 today, signaling weakened financials

Bausch Health Companies Inc. has a net debt to EBITDA ratio of 6.26x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Bausch Health Companies Inc.'s interest coverage ratio is 1.72, which means that the company struggles to meet interest obligations, signaling financial risk.

Bausch Health Companies Inc.'s profit margin was -0.48% last year and is -10.12% this year, signaling decreasing performance

Bausch Health Companies Inc.'s short-term assets of $6.15B exceed its short-term liabilities of $4.17B

Bausch Health Companies Inc.'s return on assets of -4.43% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bausch Health Companies Inc.'s return on equity of 88.77%, is higher than 15.00%, indicating good performance

Bausch Health Companies Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bausch Health Companies Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Bausch Health Companies Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Bausch Health Companies Inc. has a free cash flow yield of 47.13%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bausch Health Companies Inc.'s yearly earnings has increased 441.30% since last year from $-46.00M to $157.00M, signaling increasing performance

Bausch Health Companies Inc.'s yearly revenue has increased 7.11% since last year from $9.62B to $10.31B, signaling increasing performance

ROIC 13.07% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Bausch Health Companies Inc.'s 3-year revenue CAGR of 8.11% is positive, indicating growing revenue over the past 3 years

Bausch Health Companies Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Bausch Health Companies Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Bausch Health Companies Inc. has insufficient data to evaluate this check.

Bausch Health Companies Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bausch Health Companies Inc. is undervalued relative to its fair value price of 6.32 based on Base EBITDA Valuation model

Bausch Health Companies Inc. has an EV/EBITDA ratio of 6.92x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bausch Health Companies Inc. is undervalued relative to its fair value price of 38.91 based on Base Earnings Fair Value model

Bausch Health Companies Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Bausch Health Companies Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Bausch Health Companies Inc. has a price-to-sales ratio of 0.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue